Swaroopa Bartakke, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1902004005
Payments from drug & device makers
Across 156 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$448
- Cequr Corporation$341
- Abbott$332
- BETA Bionics, Inc.$293
- Novo Nordisk$279
- AstraZeneca$266
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,85499%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 16 | $448 |
| Cequr Corporation | 3 | $341 |
| Abbott | 23 | $332 |
| BETA Bionics, Inc. | 6 | $293 |
| Novo Nordisk | 12 | $279 |
| AstraZeneca | 10 | $266 |
| Esperion Therapeutics, Inc. | 4 | $176 |
| Corcept Therapeutics | 7 | $156 |
| Boehringer Ingelheim | 4 | $155 |
| Pfizer | 7 | $128 |
| Bayer | 6 | $125 |
| Radius Health, Inc. | 6 | $97 |
| Amneal Pharmaceuticals LLC | 5 | $96 |
| Amgen(2 entities) | 5 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $90 |
| Medtronic | 5 | $85 |
| Dexcom, Inc. | 2 | $83 |
| Tandem Diabetes Care, Inc. | 3 | $72 |
| Amryt Pharma Holdings Ltd | 3 | $69 |
| Ascensia Diabetes Care US Inc. | 3 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Nevro Corp. | 2 | $47 |
| Hologic Sales And Service, LLC | 2 | $46 |
| Mannkind Corporation | 2 | $42 |
| Inspire Medical Systems, Inc. | 1 | $39 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Merck | 2 | $34 |
| Halozyme Inc | 1 | $23 |
| Sanofi | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$438
- CeQur Simplicity$253
- Omnipod$210
- NEXLIZET$125
- NEXLETOL$125
- FARXIGA$120
- Ozempic$108
How this compares
$3,879 in reported general payments places this provider in the 45th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 438 | $681,234 |
| TrulicityDulaglutide | 154 | $224,847 |
| JardianceEmpagliflozin | 183 | $221,716 |
| MounjaroTirzepatide | 178 | $207,032 |
| FarxigaDapagliflozin Propanediol | 177 | $160,677 |
| RybelsusSemaglutide | 100 | $108,416 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $99,498 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $97,821 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 51 | $92,252 |
| Humulin R U-500Insulin Regular, Human | 39 | $68,968 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $66,052 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 59 | $64,759 |
| Xigduo XrDapaglifloz Propaned/Metformin | 63 | $61,195 |
| Bydureon BciseExenatide Microspheres | 39 | $60,193 |
| Humalog Kwikpen U-200Insulin Lispro | 31 | $54,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $279 | $836,963610 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi, Jentadueto | $155 | $304,383274 claims |
| AstraZenecaFarxiga | $266 | $160,677177 claims |
| MerckJanuvia, Janumet Xr | $34 | $81,73580 claims |
| AmgenProlia | $95 | $27,05516 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $90 | $21,69724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Stephen SharpNashville$25.9M
- Kathryn DahirNashville$11M
- Craig WierumNashville$1.7M
- Terri JerkinsNashville$1.2M
- Shichun BaoNashville$735K
- Michael MayNashville$689K
- Michael CarlsonNashville$381K
- Rodney SnowNashville$188K
- Kevin NiswenderNashville$100K
- Howard BaumNashville$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.